Journal
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Volume 36, Issue 11, Pages 3033-3040Publisher
WILEY
DOI: 10.1111/jgh.15588
Keywords
COVID-19; Crohn's disease; Latin America; Ulcerative colitis
Categories
Funding
- Helmsley Charitable Trust [2003-04445]
- National Center for Advancing Translational Sciences [UL1TR002489]
- Pfizer
- Takeda
- Janssen
- AbbVie
- Lilly
- Genentech
- Boehringer Ingelheim
- Bristol Myers Squibb
- Arenapharm
- Celltrion
- [T32DK007634]
- [K23KD111995-01A1]
Ask authors/readers for more resources
In Latin America, IBD patients diagnosed with COVID-19 have similar outcomes to global data, with risk factors for severe COVID-19 being similar to previous reports.
Background and Aim One of the most impacted regions by the pandemic globally, Latin America is facing socioeconomic and health-care challenges that can potentially affect disease outcomes. Recent data suggest that inflammatory bowel disease (IBD) patients do not have an increased risk of the development of COVID-19 complications. However, the impact of COVID-19 on IBD patients living in least developed areas remains to be fully elucidated. This study aims to describe the outcomes of IBD patients diagnosed with COVID-19 in countries from Latin America based on data from the SECURE-IBD registry. Methods Patients from Latin America enrolled in the SECURE-IBD registry were included. Descriptive analyses were used to summarize clinical and sociodemographic characteristics. The studied outcomes were (i) a composite of need for intensive care unit admission, ventilator use, and/or death (primary outcome) and (ii) a composite of any hospitalization and/or death (secondary outcome). Multivariable regression was used to identify risk factors of severe COVID-19. Results During the study period, 230 cases (Crohn's disease: n = 115, ulcerative colitis: n = 114, IBD-unclassified [IBD-U]: n = 1) were reported to the SECURE-IBD database from 13 different countries. Primary outcome was observed in 17 (7.4%) patients, and the case fatality rate was 1.7%. In the adjusted multivariable model, the use of systemic corticosteroids (odds ratio [OR] 10.97; 95% confidence interval [CI]: 3.44-34.99) was significantly associated with the primary outcome. Older age (OR 1.03; 95% CI: 1.00-1.05), systemic corticosteroids (OR 9.33; 95% CI: 3.84-22.63), and the concomitant presence of one (OR 2.14; 95% CI: 0.89-5.15) or two (OR 10.67; 95% CI: 1.74-65.72) comorbidities were associated with the outcome of hospitalization or death. Conclusion Inflammatory bowel disease patients with COVID-19 in Latin America appear to have similar outcomes to the overall global data. Risk factors of severe COVID-19 are similar to prior reports.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available